MMAE
MMAE is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. Monomethyl auristatin E or MMAE is 100-1000 times more potent than doxorubicin. It is a very potent antimitotic agent that inhibits cell division by blocking the polymerization of tubulin. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.

-
Catalog:
BP-22278
-
Name:
MMAE
-
Formula:
C39H67N5O7
-
MW:
718
-
CAS:
474645-27-7
-
Purity:
95%
-
Ships Within:
24 Hours
-
Storage Condition:
-20°C
-
Solubility:
DMSO
-
Shipping:
Ambient Temperature
-
Availability:
In Stock
-
NMR:
View
-
SDS:
View
Product Citations
- Li, W. F., Chiang, M. F., Weng, H. C., Yang, J. J., Wu, H. S., Wu, S. Y., ... & Lai, M. T. (2025). OBI-992, a Novel TROP2-Targeted Antibody–Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models. Molecular Cancer Therapeutics, 24(2), 163-175.
https://doi.org/10.1158/1535-7163.MCT-24-0588 - Samantha RB, Courtney PJ, Siteng F, et al. Thiolation of Q295: Site-Specific Conjugation of Hydrophobic Payloads without the Need for Genetic Engineering. Molecular Pharmaceuticals. 2019; 16(6): pp. 2795-2805.
https://pubs.acs.org/doi/full/10.1021/acs.molpharmaceut.9b00323